Reconsideration of sample size and power calculation for overall survival in cancer clinical trials

When designing a cancer clinical trial, it is usual to assume an exponential distribution for a time-to-event outcome such as overall survival (OS). OS is often expressed as the sum of progression-free survival (PFS) and survival post-progression (SPP), each of which is assumed to be exponentially d...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Inkyung, Ko, Hee Jung, Rha, Sun Young, Nam, Chung Mo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174257/
https://www.ncbi.nlm.nih.gov/pubmed/30302417
http://dx.doi.org/10.1016/j.conctc.2018.09.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174257/
https://www.ncbi.nlm.nih.gov/pubmed/30302417
http://dx.doi.org/10.1016/j.conctc.2018.09.007

Ejemplares similares